- Home
- ACMR vs AUPH Comparison
ACMR vs AUPH Comparison
Compare ACMR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACMR
- AUPH
- Stock Information
- Founded
- ACMR 1998
- AUPH 1993
- Country
- ACMR United States
- AUPH Canada
- Employees
- ACMR N/A
- AUPH N/A
- Industry
- ACMR Industrial Machinery/Components
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ACMR Technology
- AUPH Health Care
- Exchange
- ACMR Nasdaq
- AUPH Nasdaq
- Market Cap
- ACMR 1.3B
- AUPH 1.1B
- IPO Year
- ACMR 2017
- AUPH 1999
- Fundamental
- Price
- ACMR $24.60
- AUPH $7.77
- Analyst Decision
- ACMR Buy
- AUPH Strong Buy
- Analyst Count
- ACMR 5
- AUPH 2
- Target Price
- ACMR $30.50
- AUPH $11.50
- AVG Volume (30 Days)
- ACMR 822.1K
- AUPH 1.1M
- Earning Date
- ACMR 08-06-2025
- AUPH 07-31-2025
- Dividend Yield
- ACMR N/A
- AUPH N/A
- EPS Growth
- ACMR 19.75
- AUPH N/A
- EPS
- ACMR 1.57
- AUPH 0.27
- Revenue
- ACMR $802,274,000.00
- AUPH $247,295,000.00
- Revenue This Year
- ACMR $19.19
- AUPH $12.15
- Revenue Next Year
- ACMR $15.21
- AUPH $18.31
- P/E Ratio
- ACMR $15.54
- AUPH $29.24
- Revenue Growth
- ACMR 26.21
- AUPH 29.20
- 52 Week Low
- ACMR $13.87
- AUPH $5.20
- 52 Week High
- ACMR $30.64
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- ACMR 58.56
- AUPH 38.94
- Support Level
- ACMR $24.24
- AUPH $8.08
- Resistance Level
- ACMR $25.77
- AUPH $8.29
- Average True Range (ATR)
- ACMR 0.85
- AUPH 0.19
- MACD
- ACMR 0.04
- AUPH -0.03
- Stochastic Oscillator
- ACMR 64.31
- AUPH 5.00
About ACMR ACM Research Inc.
ACM Research Inc supplies advanced, innovative capital equipment developed for the global semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use its wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. It has designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company also develops, manufactures and sells advanced packaging tools to wafer assembly and packaging customers.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.